% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gottardo:120096,
      author       = {N. G. Gottardo and J. R. Hansford and J. P. McGlade and F.
                      Alvaro and D. M. Ashley and S. Bailey and D. L. Baker and F.
                      Bourdeaut and Y.-J. Cho and M. Clay and S. C. Clifford and
                      R. J. Cohn and C. H. Cole and P. B. Dallas and P. Downie and
                      F. Doz and D. W. Ellison and R. Endersby and P. G. Fisher
                      and T. Hassall and J. A. Heath and H. L. Hii and D.
                      Jones$^*$ and R. Junckerstorff and S. Kellie and M. Kool$^*$
                      and R. S. Kotecha and P. Lichter$^*$ and S. J. Laughton and
                      S. Lee and G. McCowage and P. A. Northcott$^*$ and J. M.
                      Olson and R. J. Packer and S. Pfister$^*$ and T. Pietsch and
                      B. Pizer and S. L. Pomeroy and M. Remke and G. W. Robinson
                      and S. Rutkowski and T. Schoep and A. A. Shelat and C. F.
                      Stewart and M. Sullivan and M. D. Taylor and B. Wainwright
                      and T. Walwyn and W. A. Weiss and D. Williamson and A.
                      Gajjar},
      title        = {{M}edulloblastoma {D}own {U}nder 2013: a report from the
                      third annual meeting of the {I}nternational
                      {M}edulloblastoma {W}orking {G}roup.},
      journal      = {Acta neuropathologica},
      volume       = {127},
      number       = {2},
      issn         = {1432-0533},
      address      = {Berlin},
      publisher    = {Springer},
      reportid     = {DKFZ-2017-00683},
      pages        = {189 - 201},
      year         = {2014},
      abstract     = {Medulloblastoma is curable in approximately $70\%$ of
                      patients. Over the past decade, progress in improving
                      survival using conventional therapies has stalled, resulting
                      in reduced quality of life due to treatment-related side
                      effects, which are a major concern in survivors. The vast
                      amount of genomic and molecular data generated over the last
                      5-10 years encourages optimism that improved risk
                      stratification and new molecular targets will improve
                      outcomes. It is now clear that medulloblastoma is not a
                      single-disease entity, but instead consists of at least four
                      distinct molecular subgroups: WNT/Wingless, Sonic Hedgehog,
                      Group 3, and Group 4. The Medulloblastoma Down Under 2013
                      meeting, which convened at Bunker Bay, Australia, brought
                      together 50 leading clinicians and scientists. The 2-day
                      agenda included focused sessions on pathology and molecular
                      stratification, genomics and mouse models, high-throughput
                      drug screening, and clinical trial design. The meeting
                      established a global action plan to translate novel biologic
                      insights and drug targeting into treatment regimens to
                      improve outcomes. A consensus was reached in several key
                      areas, with the most important being that a novel
                      classification scheme for medulloblastoma based on the four
                      molecular subgroups, as well as histopathologic features,
                      should be presented for consideration in the upcoming fifth
                      edition of the World Health Organization's classification of
                      tumours of the central nervous system. Three other notable
                      areas of agreement were as follows: (1) to establish a
                      central repository of annotated mouse models that are
                      readily accessible and freely available to the international
                      research community; (2) to institute common eligibility
                      criteria between the Children's Oncology Group and the
                      International Society of Paediatric Oncology Europe and
                      initiate joint or parallel clinical trials; (3) to share
                      preliminary high-throughput screening data across discovery
                      labs to hasten the development of novel therapeutics.
                      Medulloblastoma Down Under 2013 was an effective forum for
                      meaningful discussion, which resulted in enhancing
                      international collaborative clinical and translational
                      research of this rare disease. This template could be
                      applied to other fields to devise global action plans
                      addressing all aspects of a disease, from improved disease
                      classification, treatment stratification, and drug targeting
                      to superior treatment regimens to be assessed in cooperative
                      international clinical trials.},
      keywords     = {Antineoplastic Agents (NLM Chemicals)},
      cin          = {B062 / B060},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)B060-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:24264598},
      pmc          = {pmc:PMC3895219},
      doi          = {10.1007/s00401-013-1213-7},
      url          = {https://inrepo02.dkfz.de/record/120096},
}